Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of BEA 2180 BR in Healthy Male Subjects
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Main study: To investigate safety, tolerability, pharmacodynamics (PD) and pharmacokinetics
(PK) of BEA 2180 BR Sub-study; To investigate whether treatment with 36 μg tiotropium bromide
is able to protect of methacholine-induced bronchoconstriction compared to baseline
(methacholine challenge at screening).